



Neuland Laboratories Limited
11th Floor (5th Office Level),
Phoenix IVY Building,
Plot No.573A-III, Road No.82,
Jubilee Hills, Hyderabad - 500033,
Telangana, India.

Tel: 040 67611600 / 67611700
Email: neuland@neulandlabs.com
www.neulandlabs.com

March 22, 2024

To
BSE Limited
Phiroze Jeejeebhoy Towers, 25th Floor,
Dalal Street, Mumbai - 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We wish to inform you that the United States Food and Drug Administration (“US FDA”) has inspected our Unit 1 manufacturing facility at Bonthapally, Hyderabad from 18th to 22nd of March 2024.

The inspection at Unit 1 by the US FDA has been successfully completed, with no observations under Form 483.

This is for your information and records.

Thanking you,

Yours Sincerely,
For Neuland Laboratories Limited

Sarada Bhamidipati
Company Secretary